MPOX

SIGA Technologies Names Dr. Jay K. Varma as EVP and Chief Medical Officer

Retrieved on: 
Wednesday, September 6, 2023

NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Dr. Jay K. Varma has joined SIGA as Executive Vice President and Chief Medical Officer (CMO).

Key Points: 
  • NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Dr. Jay K. Varma has joined SIGA as Executive Vice President and Chief Medical Officer (CMO).
  • He will also continue to serve as a director of the SIGA Board of Directors.
  • “In his new additional role as EVP and Chief Medical Officer, he will be positioned to apply even more of his outstanding insight and experience to support our advocacy efforts.”
    As EVP and CMO, Dr. Varma will lead medical affairs.
  • SIGA plays a central role in helping countries around the world understand and respond to potential outbreaks of smallpox, MPOX and other orthopox viruses,” said Dr. Varma.

Mexico Needs mpox Vaccine, Says AHF and Vaccine Advocates in The Lancet Letter

Retrieved on: 
Wednesday, March 8, 2023

The European Medicines Agency and the US FDA have also authorized the use of the vaccine.

Key Points: 
  • The European Medicines Agency and the US FDA have also authorized the use of the vaccine.
  • Among the authors of this study is the highest decision-maker in public health in Mexico, Dr. Hugo López-Gatell, Undersecretary of Health.
  • The letter was accepted and finally published by the same magazine in its correspondence section titled " MPOX vaccines are needed in Mexico ,” on March 6, 2023.
  • To learn more about AHF, please visit our website: www.aidshealth.org , find us on Facebook: www.facebook.com/aidshealth and follow us on Twitter: @aidshealthcare and Instagram: @aidshealthcare .

GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections

Retrieved on: 
Monday, February 27, 2023

ATLANTA, GA, Feb. 27, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the presentation of results from a clinical study of a combinational HIV therapy that included GeoVax’s HIV vaccine candidate, MVA62B. The data were presented at the Conference on Retroviruses and Opportunistic Infections (CROI) held February 19-22, 2023, in Seattle, Washington.

Key Points: 
  • The data were presented at the Conference on Retroviruses and Opportunistic Infections (CROI) held February 19-22, 2023, in Seattle, Washington.
  • The data indicated very high levels of immunogenicity of the treatment, particularly the induction of T cell immunity, even though HIV infection compromises the immune system.
  • “The GeoVax MVA62B was previously tested in multiple clinical trials as a component of vaccine regimens designed to induce immune responses that prevent HIV infection.
  • We are continuing development of the GeoVax MVA-VLP vaccine platform targeting multiple viral diseases, including COVID-19, MPOX, Smallpox and hemorrhagic fever viruses, such as Lassa Fever and Ebola.”